Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
17737-65-4
Molecular formula
C13H11ClN2O2
Molecular weight
262.69 g/mol
Drug class
Non-steroidal anti-inflammatory drug (NSAID)nicotinic-acid derivative
Mechanism of action
The molecular mechanism is not fully characterised. As an NSAID, its pharmacology is presumed to include cyclo-oxygenase-mediated reduction of prostaglandin synthesis, contributing to analgesic and anti-inflammatory effects; this should be regarded as a class-based mechanism rather than a fully established compound-specific target profile.
Indications / reported uses
Management of pain and inflammation associated with chronic arthritic conditions and selected soft-tissue disorders in jurisdictions where clonixin is authorised
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Clonixin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Clonixin Permitted Daily Exposure (PDE) report (the Clonixin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Clonixin Occupational Exposure Limit (OEL) report (the Clonixin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.